Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit

Journal of Ocular Pharmacology and Therapeutics

Volumn 23, Issue 5, 2007, Pages 452-466

  Foy, Jeffrey W D ^a   Rittenhouse, Kay ^b   Modi, Marlene ^c   Patel, Manju ^b  

^a OSI PHARMACEUTICALS INC   (United States)

^b PFIZER INC   (United States)

^c MWM Consulting Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB; PHOSPHATE BUFFERED SALINE; VASCULOTROPIN 165;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; ELECTROCARDIOGRAPHY; ELECTRORETINOGRAPHY; FEMALE; HEMATOLOGY; LOW DRUG DOSE; MALE; MICROSCOPY; NONHUMAN; OPHTHALMOLOGY; RABBIT; URINALYSIS;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; APTAMERS, NUCLEOTIDE; DOGS; ELECTROCARDIOGRAPHY; ELECTRORETINOGRAPHY; FEMALE; INJECTIONS; INJECTIONS, INTRAVENOUS; INTRAOCULAR PRESSURE; MALE; RABBITS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 36749019706     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.0149     Document Type: Article

References (24)

1. 165): Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273:20556-20567, 1998.
2. Gragoudas, E.S., Adamis, A.P., Cunningham, E.T., Jr., et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351:2805-2816, 2004.
3. D'Amico, D.J., Masonson, H.N., Patel, M., et al. Pegaptanib sodium for neovascular age-related macular degeneration: Two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113:992-1001, 2006.
4. Cunningham, E.T., Jr., Adamis, A.P., Altaweel, M., et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112:1747-1757, 2005.
5. Wells, J.A., III, and the Pegaptanib in Central Retinal Vein Occlusion Study Group. Pegaptanib sodium for treatment of macular edema secondary to central retinal vein occlusion (CRVO). Invest. Ophthalmol. Vis. Sci. 47:E-Abstract 4279, 2006.
6. Apte, R.H., Modi, M., Masonson, H., et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 114:1702-1712, 2007.
7. Brown, D.M., Kaiser, P.K., Michels, M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1432-1444, 2006.
8. Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1419-1431, 2006.
9. Avery, R.L., Pearlman, J., Pieramici, D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695 e1-15, 2006.
10. Rich, R.M., Rosenfeld, P.J., Puliafito, C.A., et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26:495-511, 2006.
11. Nguyen, Q.D., Shah, S.M., Hafiz, G., et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113:1522-1532, 2006.
12. Gelatt, K.N., and MacKay, E.O. Distribution of intraocular pressure in dogs. Vet. Ophthalmol. 1:109-114, 1998.
13. Drolet, D.W., Nelson, J., Tucker, C.E., et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res. 17:1503-1510, 2000.
14. Jingjing, L., Srinivasan, B., Bian, X., et al. Vascular endothelial growth factor is increased following coronary artery occlusion in the dog heart. Mol. Cell. Biochem. 214:23-30, 2000.
15. Hattan, N., Warltier, D., Gu, W., et al. Autologous vascular smooth muscle cell-based myocardial gene therapy to induce coronary collateral growth. Am. J. Physiol. Heart Circ. Physiol. 287:H488-H493, 2004.
16. Ng, E.W., and Adamis, A.P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can. J. Ophthalmol. 40:352-368, 2005.
17. Ferrara, N., Chen, H., Davis-Smyth, T., et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 4:336-340, 1998.
18. Nissen, N.N., Polverini, P.J., Koch, A.E., et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am. J. Pathol. 152:1445-1452, 1998.
19. Gerber, H.P., Vu, T.H., Ryan, A.M., et al. VEGF couples hypertrophic cartilage remodeling, ossification, and angiogenesis during endochondral bone formation. Nat. Med. 5:623-628, 1999.
20. Sondell, M., Lundborg, G., and Kanje, M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J. Neurosci. 19:5731-5740, 1999.
21. 164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J. Exp. Med. 198:483-489, 2003.
22. Nishijima, K., Ng, Y.-S., Zhong, L., et al. VEGF-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 171:53-67, 2007.
23. Ferrara, N., Damico, L., Shams, N., et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859-870, 2006.
24. Avery, R.L., Pieramici, D.J., Rabena, M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372, 2006.